The global neuroendocrine tumor market is projected to grow at a CAGR of around 10% during the forecast period. The market is studied on the basis of treatment type, indication, and end-user. Amongst the indication, the global neuroendocrine tumor market is segmented into the lungs, pancreas, gastrointestinal, and others. The gastrointestinal segment holds a significant share in the market. The segmental growth is attributed to the increased incidences of gastrointestinal diseases such as colon cancer, tumor in the intestine, and many others. The rising prevalence of several gastrointestinal diseases has been recorded globally.